BNB Plus Corp. Lands Record DNA Deal Amid Risky Crypto Pivot

NEW YORK, NY – January 05, 2026 – BNB Plus Corp. (Nasdaq: BNBX) announced it has secured a $1.2 million order for its proprietary LineaDNA™ product, the largest single order for the technology in the company's history. The deal, placed by an existing global manufacturer of in vitro diagnostics (IVDs), represents a dramatic acceleration of a planned two-year purchasing cycle, now consolidated into a five-month delivery schedule slated for completion by May 2026.

This record-setting purchase provides a significant validation for the company's biotechnology division, LineaRx, Inc., highlighting surging demand for its advanced DNA production methods. However, the milestone arrives at a pivotal moment for BNB Plus Corp., a company navigating a complex and unconventional dual identity. Formerly known as Applied DNA Sciences, the firm recently rebranded and pivoted its corporate treasury towards a high-stakes strategy centered on the Binance (BNB) cryptocurrency ecosystem, creating a stark contrast between its cutting-edge scientific endeavors and its volatile digital asset ambitions.

A New Blueprint for DNA Production

The accelerated order underscores the growing market traction of the LineaDNA platform, which is positioned as a next-generation alternative to traditional DNA manufacturing. For decades, the biopharmaceutical industry has relied on plasmid-based DNA (pDNA) production, a cell-based method involving bacterial fermentation that can be time-consuming and introduce impurities like antibiotic resistance genes.

In contrast, LineaDNA is produced through a proprietary, cell-free enzymatic process leveraging large-scale Polymerase Chain Reaction (PCR). This method offers several key advantages that are becoming increasingly critical for advanced therapeutic and diagnostic applications. The technology produces high-fidelity DNA free of unwanted bacterial sequences, a crucial attribute for ensuring the safety and efficacy of products like mRNA vaccines and cell and gene therapies. According to the company, the process is also remarkably fast, capable of reducing production timelines from months to mere weeks.

This speed and purity are vital in the rapidly expanding DNA synthesis market, which was valued at nearly $5 billion in 2024 and is projected by some analysts to grow at a compound annual growth rate (CAGR) of over 19% to reach almost $30 billion by 2034. LineaRx’s ability to scale production from milligrams to grams and its operation of a Good Manufacturing Practices (GMP) facility, which became fully operational in early 2025, positions it to capture a piece of this burgeoning market.

Surging Demand in a High-Stakes Market

The decision by a major IVD manufacturer to consolidate a two-year supply into a five-month delivery window signals an urgent need within the diagnostics sector. While the customer remains unnamed, BNB Plus Corp. has confirmed the LineaDNA is a functional component in one of its cancer diagnostic tests. This urgency reflects broader trends in the IVD raw materials market, a sector estimated at over $19 billion in 2025 and driven by the global demand for earlier, faster, and more precise diagnostic tools for infectious and chronic diseases.

The accelerated timeline suggests that the customer's manufacturing and product rollout plans are pressing, and that LineaDNA provides a critical competitive advantage that cannot be easily sourced elsewhere. Inclusive of this landmark order, BNB Plus Corp. now expects to ship over $1.5 million worth of LineaDNA in the first half of 2026 alone. This follows a previously announced $600,000 follow-on order from the same client in July 2025, indicating a deepening and strategically important commercial relationship.

This commercial success provides a powerful proof-of-concept for the LineaRx subsidiary, demonstrating that its technology is not just theoretically superior but is being actively integrated into the supply chains of major global healthcare players. The order provides a much-needed revenue boost and a vote of confidence in the underlying science that has been the company's foundation for years.

The Unconventional Dual Identity of BNB Plus Corp.

While the LineaRx division celebrates its success, the parent company is charting a far more unorthodox course. In November 2025, Applied DNA Sciences officially became BNB Plus Corp., a name change reflecting a radical strategic shift. Fueled by a private investment (PIPE) offering that raised approximately $27 million, the company launched a digital asset treasury strategy focused on generating yield and gaining long-term exposure to BNB, the native token of the massive Binance blockchain ecosystem.

The rationale presented to investors is one of diversification and unlocking new forms of shareholder value by tapping into the high-growth, high-yield world of decentralized finance (DeFi). The company has brought on crypto expertise, appointing a new chairman with a background in DeFi trading to guide the strategy. Yet, this pivot has created a curious corporate hybrid: a firm with one foot in the highly regulated, science-driven world of biopharmaceuticals and the other in the volatile, largely unregulated crypto market.

This dual identity presents a complex picture for investors. The company's financial performance has been challenging; it reported revenues of just $2.14 million against staggering losses of nearly $70 million in 2025, with its stock price seeing a dramatic decline. While the new crypto strategy and its associated financing injected much-needed capital, it also tethered the company's fate to the price of BNB and the performance of complex yield-generation strategies. Analysts remain skeptical, with forecasts not anticipating profitability in the near term.

The record-setting LineaDNA order, therefore, exists in a precarious balance. It demonstrates the tangible value and commercial potential of the company's core scientific intellectual property. At the same time, the overall financial health and market perception of BNB Plus Corp. are now inextricably linked to the performance of its BNB treasury, a venture whose risks and rewards are far removed from the meticulous, data-driven progress of a laboratory.